Lexington Completes IRB Submission in Preparation for Clinical Study

Lexington Biosciences (CSE:LNB), a development-stage medical device company, is pleased to announce it has completed its requisite documentation and submitted an application for Institutional Review Board approval of its pilot clinical study.
As quoted in the press release:

In preparation for commercialization of the HeartSentry device, the pathway for regulatory approval includes a clinical study utilizing human subjects. In preparation for the study, approval by an IRB, or ethics board, is necessary before all but the most informal human research can begin.

Click here to read the full press release.